KLK3 and neuroendocrine neoplasm: In this setting, the main clinical presentations of NEPC include androgen deprivation resistance, low levels of prostate-specific antigen (PSA), the disproportion between PSA kinetic and tumor burden progression, and the eventual increase in neuroendocrine tumor markers [3,12].